Na Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Song has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ailifeiya Yilixiati
Department of Medical Oncology, The First Hospital of China Medical University
1 shared publicationHaiyang Liu
Department of Medical Oncology, the Emergency General Hospital
1 shared publication- Haizhou Li
Ganzhou Hospital of Guangdong Provincial People's Hospital, Ganzhou Municipal Hospital, Ganzhou, 341000, China.
1 shared publication Huimin Xue
Department of Medical Oncology, The First Hospital of China Medical University
1 shared publication- Jianqiao Ding
Department of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Clinical Oncology College of Dalian Medical University, Shenyang 110042, China
1 shared publication - Jijia Li
Department of Thoracic Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, 110042, Liaoning, China
1 shared publication
Latest Publications
- Open Access
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
The safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
Purpose: The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy plus esophagectomy; however, there remains a significant risk of distant metastasis following surgery, which compromises long-term survival among patients. The present study involved a meta-analysis designed to explore the safety and efficacy of neoadjuvant immunochemotherapy (nICT) in patients with locally advanced ESCC. Methods: PubMed, Embase, The Cochrane Library, and Web of Science were searched from inception until June 30, 2025. The extracted data included: pathological complete response (pCR), major pathological response (MPR), objective response rate (ORR), R 0 resection rate, the incidence of adverse events (AEs), and ≥ Grade 3 AEs. Results: Some 30 studies with a total of 1185 patients were included, wherein the treatment regimen was nICT, without restrictions on the type of immune agents. The results showed that the MPR rate after nICT was 53% (95% confidence interval (CI): 46-59%), and the pooled pCR rate was 32% (95% CI: 29-35%). The pooled R 0 resection was 97% (95% CI: 96-98%), and the pooled ORR rate was 68% (95% CI: 64-72%). The incidence of ≥ Grade 3 treatment-related adverse events (TrAEs) was 26% (95% CI: 17-38%), the incidence of ≥ Grade 3 surgery-related adverse events (SrAEs) was 3% (95% CI: 1-5%), and the main TrAEs in hematological toxicity were leukopenia, neutropenia, and thrombocytopenia. The main symptoms of non-hematological-toxicity TrAEs were nausea, vomiting, fatigue, decreased appetite, and rash. Infection and anastomotic fistula were the most common postoperative complications. In all, 9 cases of surgery-related deaths were identified. Among them, 3 cases were pulmonary complications (all related to pneumonia), 3 cases were direct surgery-related complications (hemorrhagic shock, anastomotic leakage complicated with hemorrhage, and esophagotracheal fistula, respectively), 1 case was severe infection, and 2 cases were attributed to unspecified causes (fatal due to surgery-related Grade V adverse events). Fatal surgical complications were uncommon. Conclusions: This study preliminarily indicates the efficacy and safety of nICT in locally advanced ESCC in China. This combination regimen exhibits superior pCR with tolerable safety profiles, suggesting a new therapeutic strategy for patients with locally advanced ESCC. (CRD42024574607). Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574607 , identifier CRD42024574607.
- 10 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessThe safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
Purpose: The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy plus esophagectomy; however, there remains a significant risk of distant metastasis following surgery, which compromises long-term survival among patients. The present study involved a meta-analysis designed to explore the safety and efficacy of neoadjuvant immunochemotherapy (nICT) in patients with locally advanced ESCC. Methods: PubMed, Embase, The Cochrane Library, and Web of Science were searched from inception until June 30, 2025. The extracted data included: pathological complete response (pCR), major pathological response (MPR), objective response rate (ORR), R 0 resection rate, the incidence of adverse events (AEs), and ≥ Grade 3 AEs. Results: Some 30 studies with a total of 1185 patients were included, wherein the treatment regimen was nICT, without restrictions on the type of immune agents. The results showed that the MPR rate after nICT was 53% (95% confidence interval (CI): 46-59%), and the pooled pCR rate was 32% (95% CI: 29-35%). The pooled R 0 resection was 97% (95% CI: 96-98%), and the pooled ORR rate was 68% (95% CI: 64-72%). The incidence of ≥ Grade 3 treatment-related adverse events (TrAEs) was 26% (95% CI: 17-38%), the incidence of ≥ Grade 3 surgery-related adverse events (SrAEs) was 3% (95% CI: 1-5%), and the main TrAEs in hematological toxicity were leukopenia, neutropenia, and thrombocytopenia. The main symptoms of non-hematological-toxicity TrAEs were nausea, vomiting, fatigue, decreased appetite, and rash. Infection and anastomotic fistula were the most common postoperative complications. In all, 9 cases of surgery-related deaths were identified. Among them, 3 cases were pulmonary complications (all related to pneumonia), 3 cases were direct surgery-related complications (hemorrhagic shock, anastomotic leakage complicated with hemorrhage, and esophagotracheal fistula, respectively), 1 case was severe infection, and 2 cases were attributed to unspecified causes (fatal due to surgery-related Grade V adverse events). Fatal surgical complications were uncommon. Conclusions: This study preliminarily indicates the efficacy and safety of nICT in locally advanced ESCC in China. This combination regimen exhibits superior pCR with tolerable safety profiles, suggesting a new therapeutic strategy for patients with locally advanced ESCC. (CRD42024574607). Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574607 , identifier CRD42024574607.
- Open Access
- 2 May 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-13
C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance. MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth. MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression. Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.
- 2 May 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-13
Open AccessC-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood. Here we examined whether ER-c-Src-HER2 complex formation is involved in tamoxifen resistance. MTT and colony formation assays were used to measure cell viability and proliferation. Western blot was used to detect protein expression and protein complex formations were detected by immunoprecipitation and immunofluorescence. SiRNA was used to examine the function of HER2 in of BT474 cells. An in vivo xenograft animal model was established to examine the role of c-Cbl in tumor growth. MTT and colony formation assay showed that BT474 cells are resistant to tamoxifen and T47D cells are sensitive to tamoxifen. Immunoprecipitation experiments revealed ER-c-Src-HER2 complex formation in BT474 cells but not in T47D cells. However, ER-c-Src-HER2 complex formation was detected after overexpressing HER2 in T47D cells and these cells were more resistant to tamoxifen. HER2 knockdown by siRNA in BT474 cells reduced ER-c-Src-HER2 complex formation and reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab. Nystatin, a lipid raft inhibitor, reduced ER-c-Src-HER2 complex formation and partially reversed tamoxifen resistance. ER-c-Src-HER2 complex formation was disrupted by overexpression of c-Cbl but not by the c-Cbl ubiquitin ligase mutant. In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. The effect of c-Cbl was validated in BT474 tumor-bearing nude mice in vivo. Immunofluorescence also revealed ER-c-Src-HER2 complex formation was reduced in tumor tissues of nude mice with c-Cbl overexpression. Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex.
- 1 June 2015
- Published by Elsevier in Cellular Immunology
- Vol. 295 (2) , 77-82
Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens
- 1 June 2015
- Published by Elsevier in Cellular Immunology
- Vol. 295 (2) , 77-82
Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens
- Open Access
- 4 April 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (4) , 5838-5851
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Aberrant MET expression and hepatocyte growth factor (HGF) signaling are implicated in promoting resistance to targeted agents; however, the induced MET activation by epidermal growth factor receptor (EGFR) inhibitors mediating resistance to targeted therapy remains elusive. In this study, we identified that cetuximab-induced MET activation contributed to cetuximab resistance in Caco-2 colon cancer cells. MET inhibition or knockdown sensitized Caco-2 cells to cetuximab-mediated growth inhibition. Additionally, SRC activation promoted cetuximab resistance by interacting with MET. Pretreatment with SRC inhibitors abolished cetuximab-mediated MET activation and rendered Caco-2 cells sensitive to cetuximab. Notably, cetuximab induced MET/SRC/EGFR complex formation. MET inhibitor or SRC inhibitor suppressed phosphorylation of MET and SRC in the complex, and MET inhibitor singly led to disruption of complex formation. These results implicate alternative targeting of MET or SRC as rational strategies for reversing cetuximab resistance in colon cancer.
- 4 April 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (4) , 5838-5851
Open AccessCetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Aberrant MET expression and hepatocyte growth factor (HGF) signaling are implicated in promoting resistance to targeted agents; however, the induced MET activation by epidermal growth factor receptor (EGFR) inhibitors mediating resistance to targeted therapy remains elusive. In this study, we identified that cetuximab-induced MET activation contributed to cetuximab resistance in Caco-2 colon cancer cells. MET inhibition or knockdown sensitized Caco-2 cells to cetuximab-mediated growth inhibition. Additionally, SRC activation promoted cetuximab resistance by interacting with MET. Pretreatment with SRC inhibitors abolished cetuximab-mediated MET activation and rendered Caco-2 cells sensitive to cetuximab. Notably, cetuximab induced MET/SRC/EGFR complex formation. MET inhibitor or SRC inhibitor suppressed phosphorylation of MET and SRC in the complex, and MET inhibitor singly led to disruption of complex formation. These results implicate alternative targeting of MET or SRC as rational strategies for reversing cetuximab resistance in colon cancer.